Clinical Trial Update: Treating Kidney Donors With Valganciclovir to Reduce Viral Transmission to Recipients [Phase 2]

View source ↗

Summary

Phase 2 trial investigating valganciclovir in kidney donors to reduce viral transmission (EBV/CMV viremia) to recipients; study completed with results posted in…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cmv Viremia
• Ebv Viremia

Drugs mentioned

• Valganciclovir (Valganciclovir)

Snippet

Sponsor: University of Minnesota | Conditions: EBV Viremia, CMV Viremia | Phase 2 | Status: COMPLETED | Results posted: 2014-06-20